DORITHRICIN THROAT LOZENGES

Šalis: Singapūras

kalba: anglų

Šaltinis: HSA (Health Sciences Authority)

Veiklioji medžiaga:

BENZALKONIUM CHLORIDE; BENZOCAINE; TYROTHRICIN

Prieinama:

HYPHENS PHARMA PTE. LTD.

ATC kodas:

R02AA20

Dozė:

1.0 mg

Vaisto forma:

LOZENGE

Sudėtis:

BENZALKONIUM CHLORIDE 1.0 mg; BENZOCAINE 1.5 mg; TYROTHRICIN 0.5 mg

Vartojimo būdas:

ORAL

Recepto tipas:

Pharmacy Only

Pagaminta:

Medice Arzneimittel Pütter GmbH & Co. KG

Autorizacija statusas:

ACTIVE

Leidimo data:

1990-05-03

Pakuotės lapelis

DORITHRICIN
® THROAT LOZENGES
Important information, read carefully!
COMPOSITION ______________ (per lozenge)
Tyrothricin _______________ 0,50 mg
Benzalkonium chloride _______ 1,00 mg
Benzocaine ________________ 1,50 mg
The other ingredients are:
Sorbitol
(Ph.
Eur.),
talc,
sucrose
stearate
type
III,
saccharin-sodium
2H
2
O,
mint
oil,
providone (K 25), carmellose sodium
For diabetic patients: 1 lozenge contains 870,7 mg sorbitol
PROPERTIES
Dorithricin
®
Throat Lozenges are highly effective in the treatment of painful
inflammations of
the oral cavity and pharynx. They are fast painkillers due to the
proven surface anaesthetic
Benzocaine. Their high antimicrobial effect inhibits infection. The
efficacy of the specific
topical antibiotic Tyrothricin, which is germ-hindering and germicidal
and Benzalkonium
chloride,
which is
antiseptic
highly
effective
are both
directed
at
the most frequently
occurring germs which produce painful inflammations in the oral cavity
and pharynx.
By
combining
the
two
antimicrobial
active
substances,
the
main
pathogens
are
also
overcome.
Dorithricin
®
Throat Lozenges are well-tolerated, conducive to mucosa regeneration,
and
speed up the healing process.
INDICATIONS
Sore
throat,
stomatitis
(inflammation
of
the
mouth),
pharyngitis
(inflammation
of
the
pharynx), laryngitis (inflammation of the larynx), gingivitis
(inflammation of the gums).
CONTRAINDICATIONS
None known. Generally well-tolerated.
INCOMPATIBILITIES
None known.
DRUG INTERACTIONS
Patients that are administered local anaesthetics may be at increased
risk of developing
methaemoglobinaemia when concurrently exposed to the following
oxidizing agents:

Nitrates/Nitrites (eg. nitroglycerin, nitroprusside, nitric oxide,
nitrous oxide)

Local
anaesthetics
(eg.
lidocaine,
bupivacaine,
mepivacaine,
tetracaine,
prilocaine,
procaine, articaine)

Antineoplastic
agents
(eg.
cyclophosphamide,
flutamide,
rasburicase,
isofamide,
hydroxyurea)

Antibiotics (eg. dapsone, sulphonamides, nitrofurantoin,
para-aminosalicylic acid)

Anti